

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company “

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. “

Item 1.02 Termination of a Material Definitive Agreement.

On November 1, 2018, CTI BioPharma Corp. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC (“Cowen”) to sell shares of the Company’s common stock, par value \$0.001 per share, having aggregate sales proceeds of up to \$50,000,000, from time to time, through an “at the market” equity offering program under which Cowen acted as sales agent.

On March 21, 2019, the Company provided notice to Cowen terminating the Sales Agreement effective as of March 27, 2019.

The foregoing description of the Cowen Sales Agreement is not complete and is qualified in its entirety by reference to the full text of the Sales Agreement, a copy of which is filed as Exhibit 1.1 to the Company’s Current Report on Form 8-K filed with the SEC on November 1, 2018.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CTI BIOPHARMA CORP.

Date: March 22, 2019 By: /s/ David H. Kirske
David H. Kirske
Chief Financial Officer